Grab Sources And More From The CMND Company Presentation.
-----
And as I mentioned above, CMND has several potential catalysts that could provide a breakout spark near term. Here they are:
No. 1 CMND Potential Catalyst - A Tiny Float Could Provide Access To Extreme Volatility
According to the Yahoo Finance website, CMND has a tiny float.
The website reports this profile to have approximately 1.29Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
-----
No. 2 CMND Potential Catalyst - Clearmind Continues Its Progress Toward FIH Clinical Trial For CMND-100
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psych-e-delic-derived drug candidate, the MEAI- based molecule- CMND-100.
The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound.
"Clearmind continues its progress toward FIH clinical trial," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. "This milestone joins other achievements we've made in a relatively short period. Non-clinical data generated to date demonstrate that our MEAI- based treatment has the potential to treat a broad range of addictions and binge behaviors such as AUD."
"Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use," she added. "Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition."
The Company previously announced that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development of CMND-100.
Read the full article here.
-----
No. 3 CMND Potential Catalyst - Nasdaq Uplisting Creates Incredible Exposure Opp.
Clearmind Medicine Announces Closing of $7.5Mn Public Offering and Uplisting to the Nasdaq Capital Market
VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), ..., today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of $6.50 per share (CAD$8.65), for aggregate gross proceeds of $7.5Mn, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse st-ock split, which was effective at 5:30 p.m. on September 30, 2022.
...
Read the full article here.
Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ:CMND).
Read the full article here.
-----
No. 4 CMND Potential Catalyst - Company Files Provisional Patent Application Related To Metabolic Syndromes (Including Obesity)
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.
VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), ..., today announced it has filed a provisional patent application related to metabolic syndromes including obesity.
The patent application is another result of the company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem.
The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind's MEAI, a novel proprietary psych-e-delic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™, which is used for treating obesity and its related metabolic disorders.
"Food addiction and obesity are an epidemic raging in the United States and around the world, yet there are few safe and effective anti-obesity treatments on the market," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
"In pre-clinical studies MEAI has shown great potential in its ability to treat different addictions. Certain metabolic syndromes Can be associated to addictive behaviors, and we believe combining MEAI with SciSparc's CannAmide™ may create a valuable tool for treating these conditions."
The study was conducted as part of Clearmind’s research and development projects with the Hebrew University’s Obesity and Metabolism Laboratory, which is led by Joseph Tam, D.M.D., Ph.D., Associate Professor of Pharmacology at the University’s Institute for Drug Research.
“This new patent application continues Clearmind’s strategy since inception to enhance its IP portfolio to create state-of-the-art psych-e-delic drug candidates, to better serve patients in need,” said Dr. Zuloff-Shani.
Read the full article here.
-----
CMND Recap - This Nasdaq's Top 4 Potential Breakout Catalysts
No. 1 - A Tiny Float Could Provide Access To Extreme Volatility
No. 2 - Clearmind Continues Its Progress Toward FIH Clinical Trial For CMND-100
No. 3 - Nasdaq Uplisting Creates Incredible Exposure Opp.
No. 4 - Company Files Provisional Patent Application Related To Metabolic Syndromes (Including Obesity)
-----
Coverage is officially initiated on CMND. When time permits, do this:
